Home/Pipeline/Curadigm Platform Programs

Curadigm Platform Programs

Undisclosed

Discovery/PreclinicalActive

Key Facts

Indication

Undisclosed

Phase

Discovery/Preclinical

Status

Active

Company

Nanobiotix

About Nanobiotix

Nanobiotix's mission is to transform cancer treatment by developing disruptive, physics-based nanotherapeutics, beginning with its lead radioenhancer candidate, NBTXR3. Key achievements include establishing a pivotal-stage global program in head and neck cancer and securing a landmark strategic collaboration with Janssen (Johnson & Johnson) for NBTXR3's co-development and commercialization. The company's strategy leverages its proprietary nanoparticle platform to create treatments that are biologically agnostic, aiming to improve radiotherapy outcomes and potentially prime anti-tumor immunity across a wide range of solid tumors.

View full company profile

Therapeutic Areas

Oncology

Other Undisclosed Drugs

Drug	Company	Phase	Status
Preclinical ISAC 1	Bolt Biotherapeutics	Preclinical	Available for Partnering
Preclinical ISAC 2	Bolt Biotherapeutics	Preclinical	Available for Partnering
ART12.11	Artelo Biosciences	Preclinical	Active
Novel Vaccines	MSD	Development	Active
SLS-009	Seelos Therapeutics	Discovery	Research
Measovir®-based Prophylactic Vaccine (with Unither)	Oncovita	Research/Pre-clinical	Early-stage collaboration
Internal sdAb Discovery Program	NanoTag Biotechnologies	Discovery	Active
Amgen Collaboration Program	Xeris Biopharma	Pre-clinical	Active
NB-701	Nerai Biosciences	Discovery	Active
Undisclosed Therapeutic Program(s)	Bright Cell	Clinical Trial (Phase unspecified)	Active
Biosimilars Pipeline	Intelligent Therapeutics	Pre-clinical/Development	Active
Proprietary Therapeutic Pipeline	Excelsior Sciences	Discovery	Active